Mediwound Ltd

The medium-term structure remains bearish under Stage 4, despite extreme oversold conditions and a Post-Capitulation pattern suggesting exhaustion. Price continues to trade below declining EMAs, lacking acceptance above key moving averages. Short entries remain premature; the optimal engagement is to trim on rallies into the down-sloping EMA zone and prior support-turned-resistance region.

• ↑2026 revenue guidance at $24–26M, targeting strong YoY recovery
• ↑NexoBridge facility expands capacity six-fold, operational by end-2025
• ↓Q1 2026 revenue fell to $1.5M from $4M in Q1 2025